The majority of these reactions appeared within 48 hours of vaccination and spontaneously resolved over an average of 4 days without sequelae. Serological correlates for protection against pertussis have not been established. REPEVAX should not be used for primary immunization. Please remove one or more studies before adding more. This site uses cookies. REPEVAX can be used in the management of tetanus prone injuries with or without concomitant administration of Tetanus Immunoglobulin according to official recommendations. Do not freeze. In both age groups, injection site pain was the most common adverse reaction. Limited clinical data have shown there is interference with the immune response to other antigens (i.e. The stoppers, plunger stoppers and caps for all presentations of REPEVAX are latex-free. For the full list of excipients, see section 6.1. For instructions on handling of the medicinal product before administration, see section 6.6. It allows continued monitoring of the benefit/risk balance of the medicinal product. In both studies the rates of most systemic adverse events within 7 to 10 days following vaccination were less than 10%. REPEVAX appears as a uniform, cloudy, white suspension. In serology follow-up studies conducted with REPEVAX, seroprotective antibody levels (≥1:8 dilution) for each poliovirus (type1, 2 and 3) were maintained in 95% to 100% of the children, adolescents and adults at the 5-year follow-up time point, and in 100% of the adolescents at the 10-year follow-up time point. The clinical relevance of this observation is unknown. REPEVAX may be administered concurrently with a dose of recombinant Human Papillomavirus vaccine with no significant interference with antibody response to any of the components of either vaccine. • The effectiveness of maternal immunization against pertussis in the first 3 months of life has been estimated to be >90%. COVID-19 is an emerging, rapidly evolving situation. Une pétition a été lancé sur Internet par un professeur. Parenteral products should be inspected visually for extraneous particulate matter and/or discoloration prior to administration. • 82.4% and 92.7% were seroprotected against diphtheria at a threshold ≥0.1 and ≥0.01 IU/mL, respectively. 2Age at which subjects received a dose of ADACEL, 3Percentage of subjects with antibodies ≥ 4 EU/mL for PT, FHA and PRN, and ≥ 17 EU/mL for FIM for the 3 year follow-up; ≥ 4 EU/mL for PT, FIM and PRN, and ≥ 3 EU/mL for FHA for the 5-year and 10-year follow-up.  (Clinical Trial), A Double Blind, Controlled, Randomised, Clinical Study to Assess the Safety of Repevax® Administered One Month After Revaxis® or Placebo to Healthy Adults, Active Comparator: REPEVAX® after Placebo. REPEVAX peut être administré simultanément avec une dose de vaccin contre l'Hépatite B. REPEVAX peut être administré simultanément avec une dose de vaccin papillomavirus humain recombinant, sans interférence clinique significative avec la réponse en anticorps vis-à … The safety profile of REPEVAX in 390 children 3 to 6 years of age as presented in Table 1 is derived from two clinical studies: - In a clinical study, 240 children were primed at 3, 5 and 12 months of age with a DTaP vaccine with no additional dose in the second year of life. Continue typing to refine. One month post-vaccination ≥ 98.5% of study participants achieved seroprotective antibody levels (≥ 0.1 IU/ml) for diphtheria and tetanus, and ≥ 84% achieved booster responses to the pertussis antigens. To bookmark a medicine you must sign up and log in. As with all injectable vaccines, appropriate medical treatment and supervision should be readily available for immediate use in case of a rare anaphylactic reaction following the administration of the vaccine. La contamination se fait principalement par voie digestive, lors de la consommation d'eau contaminée, d'aliments souillés (crudités, par exemple), ou par les mains sales. Ce virus n'existe que chez l'être humain. Precautions to be taken before handling or administering the medicinal product. Separate limbs must be used for the site of injection. The safety and immunogenicity of REPEVAX in adults and adolescents was shown to be comparable to that observed with a single booster dose of Td adsorbed or Td Polio adsorbed vaccines containing a similar amount of tetanus and diphtheria toxoids and inactivated poliovirus types 1, 2 and 3. (See Table 1). The immune responses of adults, adolescents and children 3 to 6 years of age one-month after vaccination with REPEVAX are shown in the table below. Discard the vaccine if it has been frozen. Toutes les présentations peuvent ne pas être commercialisées. Table 1 presents adverse reactions observed in clinical trials and also includes additional adverse events which have been spontaneously reported during the post-marketing use of REPEVAX worldwide. Passive protection against pertussis in early infancy following maternal immunization during pregnancy (see sections 4.2, 4.4, 4.6 and 5.1). The number and schedule of doses should be determined according to local recommendations. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. Therefore, the frequency category “Not known” is assigned to these adverse events. Only fever (≥37.5°C) and fatigue were reported in more than 10 % of subjects 3 to 6 years of age. Most commonly reported reactions following vaccination included local reactions at the injection site (pain, redness and swelling). Passive protection of neonates and infants against pertussis. As with any vaccine, a protective immune response may not be elicited in all vaccines (see section 5.1). Why Should I Register and Submit Results? 0.5 mL of suspension in pre-filled syringe (glass) with a plunger stopper (chlorobromobutyl or bromobutyl or chlorobutyl elastomer), without attached needle, with a tip-cap (chlorobromobutyl elastomer or synthetic isoprene-bromobutyl elastomer) - pack size of 1, 10 or 20. The normal appearance of the vaccine is a uniform cloudy, white suspension which may sediment during storage. The benefits versus the risk of administering REPEVAX to breastfeeding women should be evaluated by the health-care providers. Based on findings from multiple studies of REPEVAX and ADACEL administered to pregnant women primarily during the 2nd or 3rd trimester of gestation: • Pertussis antibody responses in pregnant women are generally similar to those in non-pregnant women. L’ordonnance, prévue à l’article 38 de la Constitution, peut être assimilée à un contournement de cette règle. What REPEVAX is and what it is used for 2. Active immunization against diphtheria, tetanus, pertussis and poliomyelitis in persons from 3 years of age as a booster following primary immunization. (A pertussis booster response was defined as a post-vaccination antibody concentration ≥ 4 times the LLOQ if the pre-vaccination level was < LLOQ; ≥ 4 times the pre-vaccination level if that was ≥ LLOQ but < 4 times LLOQ; or ≥ 2 times the pre-vaccination level if that was ≥ 4 times the LLOQ). One additional dose of a diphtheria- and tetanus- (dT) containing vaccine can be administered one month later followed by a 3rd dose of a diphtheria or dT containing vaccine 6 months after the first dose to optimize protection against disease (see section 5.1). ** EU = ELISA units: Antibody levels of >5 EU/mL were postulated as possible surrogate markers for protection against pertussis by Storsaeter J. et al, Vaccine 1998;16:1907-16. Suspension for injection in pre-filled syringe. Intramuscular injections should be given with care in patients on anticoagulant therapy or suffering from coagulation disorders because of the risk of haemorrhage. This is based on the results from a clinical trial in which REPEVAX was administered concomitantly with the first dose of Gardasil (see section 4.8). The highest frequency from either study is presented. Plusieurs chaînes de pharmacies, notamment au Caire, sont ouvertes 24h/24. diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated). Nos vaccins - Repevax. Listing a study does not mean it has been evaluated by the U.S. Federal Government. La poliomyélite est une infection due à un virus qui provoque des paralysies en attaquant le système nerveux. Pour accéder à l'ensemble des informations concernant Repevax, cliquez sur l'une de ses formes présentées dans … 1Eligible subjects for whom immunogenicity data was available for at least one antigen at the specified time-point. To describe the safety of TdaP-IPV vaccine (REPEVAX®) administered one month after Td-IPV vaccine (REVAXIS®) or one month after Placebo. However, in most of the cases, the antibody concentrations remain above the thresholds established as protective. Keep the container in the outer carton in order to protect from light. • Maternal antibody directed against pertussis antigens persists for 2 to 4 months after birth and may be associated with blunting of the infant immune response to active immunization against pertussis (see section 4.4). REPEVAX has not been evaluated in fertility studies. On comparison with data from the Sweden I pertussis efficacy trials conducted between 1992 and 1996, where primary immunization with Sanofi Pasteur Limited's acellular pertussis infant DTaP formulation confirmed a protective efficacy of 85% against pertussis disease, it is considered that REPEVAX had elicited protective immune responses. REPEVAX; VAXELIS; Légende Médicament ayant des présentations disponibles sans ordonnance. Comme le repevax contient des germes inactifs, il peut être injecté, simultanément avec une dose de vaccin contre : La grippe, à condition que le médicament contient des germes inactifs. Syncope (fainting) can occur following, or even before, administration of injectable vaccines, including REPEVAX. 410, Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. • As with other vaccines, administration of REPEVAX should be postponed in persons suffering from an acute severe febrile illness. Adverse events in children were collected from clinical trials conducted in 3 to 5 years of age and 5 to 6 years of age. Start typing to retrieve search suggestions. Procedures should be in place to prevent falling injury and manage syncopal reactions. Interaction studies have not been carried out with other vaccines, biological products or therapeutic medications. Dites-le au vaccinateur (s'il est infirmier, en principe il faut une ordonnance). By continuing to browse the site you are agreeing to our policy on the use of cookies. The presence of a minor infection (e.g., mild upper respiratory infection) is not a contraindication. Pivotal studies conducted with ADACEL provide serology follow-up data at 3, 5 and 10 years, in individuals previously immunized with a single booster dose of ADACEL. There was a trend for higher rates of local and systemic reactions in adolescents than in adults. Pharmacotherapeutic Group: Vaccine against diphtheria, tetanus, pertussis and poliomyelitis. Prevenar ® est un vaccin administré aux adultes, aux adolescents et aux nourrissons en vue d'immuniser contre certaines infections, otites et pneumonies dues à la bactérie Streptococcus pneumoniae. pour demander que le vaccin DT Polio simple et sans aluminium soit de nouveau disponible en France. A single injection of one (0.5 mL) dose is recommended in all indicated age groups. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Table 4: Serological immune status (seroprotection/seroresponse rates and GMC/GMT) before vaccination and after each dose of a 3 dose-vaccination schedule including REPEVAX® (Dose 1) followed by 2 doses of REVAXIS® 1 and 6 months later (Dose 2 and 3) in subjects vaccinated according to protocol (FAS), GMC: Geometric mean of antibody concentrations; GMT: Geometric mean of antibody titres; CI: Confidence Interval; SN: seroneutralisation; ELISA: Enzyme Linked Immunoassay; dil: dilution. In adolescents and adults with an unknown or incomplete diphtheria or tetanus vaccination status against diphtheria or … U.S. Department of Health and Human Services, The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. No teratogenic effect of vaccines containing diphtheria or tetanus toxoids, or inactivated poliovirus has been observed following use in pregnant women. Reporting suspected adverse reactions after authorisation of the medicinal product is important. What you need to know before REPEVAX is given to you or your child 3. The clinical relevance of this observation is unknown. In the case of immunosuppressive therapy please refer to Section 4.4. 0.5 mL of suspension in pre-filled syringe (glass) with a plunger stopper (chlorobromobutyl or bromobutyl or chlorobutyl elastomer) with attached needle and needle guard (translucent polypropylene rigid safeshield and polyisoprene) - pack size of 1, 10 or 20. To describe the safety of Td-IPV vaccine (REVAXIS®) or Placebo administered to healthy adults. These children received REPEVAX at 5 to 6 years of age. When suggestions are available use up and down arrows to review and ENTER to select. Toute reproduction ou représentation totale ou partielle de ce site par quelque procédé que ce soit, sans … Enfants âgés de 3 à 5 ans (150 sujets) Cent cinquante enfants ayant reçu une primovaccination à 2, 3 et 4 mois avec un vaccin combiné diphtérique, tétanique et coquelucheux germes entiers (sans dose additionnelle dans la seconde année de vie) ont été vaccinés avec REPEVAX à l’âge de 3 à 5 ans. Le vaccin contre l'hépatite B (en anglais, Hepatitis B vaccine ou HBV) prévient la contamination par le virus de l'hépatite B depuis 1982. Safety of REPEVAX® Given One Month After REVAXIS® The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The clinical significance of this observation is not known. They all resolved without sequelae. A persistent nodule at the site of injection may occur with all adsorbed vaccines, particularly if administered into the superficial layers of the subcutaneous tissue. Nevertheless, vaccination of HIV infected persons or persons with chronic immunodeficiency, such as AIDS, is recommended even if the antibody response might be limited. The effect of administration of REPEVAX during lactation has not been assessed. In the event of either being observed, discard the medicinal product. avec aiguille attachée – boîte de 1, 10 ou 20. As with other inactivated vaccines, it is not expected that vaccination with REPEVAX during any trimester would harm the fetus. La vaccination contre la diphtérie, le tétanos et la poliomyélite (DTP) est obligatoire ou simplement recommandée selon l'âge et la situation de la personne. After administration of one dose of REPEVAX to 330 adults ≥40 years of age that had not received any diphtheria- and tetanus-containing vaccine in the past 20 years: • ≥95.8% of adults were seropositive (≥ 5 IU/mL) for antibodies to all vaccine-containing pertussis antigens. What REPEVAX is and what it is used for REPEVAX (Tdap-IPV) is a vaccine. Regarding the interval between a booster dose of REPEVAX and preceding booster doses of diphtheria and/or tetanus containing vaccines, the official recommendations should generally be followed. These signs and symptoms usually were mild in intensity and occurred within 48 hours following vaccination (Adverse Events have been observed within 24 hours and 7 days following vaccination in children 3 through 6 years). 0.5 mL of suspension in pre-filled syringe (glass) with a plunger stopper (chlorobromobutyl or bromobutyl or chlorobutyl elastomer), without attached needle, with a tip-cap (chlorobromobutyl elastomer or synthetic isoprene-bromobutyl elastomer ) and 1 or 2 separate needles - pack size of 1 or 10. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. REPEVAX, suspension injectable en seringue préremplie. Based on the serology follow-up and repeat vaccination data, REPEVAX can be used instead of a dT vaccine or dT-IPV vaccine to boost immunity to pertussis in addition diphtheria, tetanus and polio. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00400309. Qualitative and quantitative composition, 4.2 Posology and method of administration, 4.4 Special warnings and precautions for use, 4.5 Interaction with other medicinal products and other forms of interaction, 4.7 Effects on ability to drive and use machines, 6.6 Special precautions for disposal and other handling, 9. In a clinical trial of 843 healthy adolescent males and females 11-17 years of age, administration of the first dose of Gardasil concomitantly with REPEVAX showed that there was more injection-site swelling and headache reported following concomitant administration. Plus ou moins intenses, de durée variable, ces douleurs peuvent être très handicapantes au … The risk appears to be dependent on the number of prior doses of d/DTaP vaccine, with a greater risk following the 4th and 5th doses. In the absence of compatibility studies, REPEVAX must not be mixed with other medicinal products. Information provided by (Responsible Party): Sanofi ( Sanofi Pasteur, a Sanofi Company ). However, in accordance with commonly accepted immunization guidelines, since REPEVAX is an inactivated product it may be administered concomitantly with other vaccines or immunoglobulins at separate injection sites. Talk with your doctor and family members or friends about deciding to join a study. Des milliers de personnes souffrent régulièrement de maux de tête ou céphalées. Il est présent dans les selles des personnes contaminées. REPEVAX can be used for repeat vaccination to boost immunity to diphtheria, tetanus and pertussis at 5 to 10 year intervals (see section 5.1). Evaluation of pharmacokinetic properties is not required for vaccines. REPEVAX may be administered to pregnant women during the second or third trimester to provide passive protection of infants against pertussis (see sections 4.1, 4.4, 4.6 and 5.1). • 98.5% and 99.7% were seroprotected against tetanus at a threshold ≥0.1 and ≥0.01 IU/mL, respectively. Healthy adult, with vaccination history (by written evidence) of a minimum of 5 doses of a tetanus, diphtheria and poliomyelitis containing vaccine as recommended in the French vaccination calendar at 18 years old, and a maximum of 8 doses. Possible side effects 5. In adolescents and adults with an unknown or incomplete diphtheria or tetanus vaccination status against diphtheria or tetanus, one dose of REPEVAX® can be administered as part of a vaccination series to protect against pertussis and poliomyelitis and in most cases also against tetanus and diphtheria. Last dose of a tetanus and/or diphtheria and/or poliomyelitis containing vaccine administered either alone or in combination at least 5 years prior to the administration of the first study vaccine. REPEVAX est indiqué pour : - l'immunisation active contre la diphtérie, le tétanos, la coqueluche et la poliomyélite chez les sujets à partir de l'âge de 3 ans en rappel après primovaccination. For general information, Learn About Clinical Studies. Adverse reactions are ranked under headings of frequency using the following convention: cannot be estimated from the available data.